Development of a Biorelevant Dissolution Test Using Bicarbonate Buffer and Apex Vessel to Predict Clinical Bioequivalence
Chemical and Pharmaceutical Bulletin · 2026
DOI: 10.1248/cpb.c25-00583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, 2026. Verfasst von Masahiro Fushimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sawai Pharmaceutical Co., Ltd., 5-2-30 Miyahara, Yodogawa-ku, Osaka 532-0003, Japan. Hauptthemen laut MEDLINE: Bicarbonates, Esomeprazole. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Bioequivalence (BE) studies are essential for confirming therapeutic equivalence. However, current compendial dissolution tests do not necessarily provide a reliable prediction of clinical BE. We aimed to develop a biorelevant dissolution test that predicts clinical bioequivalence (BE). Three enteric-coated pellets of esomeprazole magnesium trihydrate (ECP-ESO), either clinically BE or non-BE (NBE), were evaluated. Dissolution tests were performed using the paddle method (pH 6.5 or 6.8, 25-100 rpm, 500 mL, 37°C). Biorelevant bicarbonate buffer (BCB) was used as a simulated intestinal fluid, with a floating lid applied to prevent CO2 escape and maintain pH. Hydrodynamics that suppresses artifact cone formation (coning) were produced using an apex vessel (Apex-V). These biorelevant conditions were compared with the compendial phosphate buffer (PPB) and the round-bottom vessel (RB-V). RB-V is considered less biorelevant as it causes coning at the vessel bottom. When PPB and RB-V were used, BE and NBE formulations could not be distinguished. Substitution of RB-V with Apex-V eliminated coning but lacked discriminative power. This outcome was also observed with BCB and RB-V. Combining both BCB and Apex-V successfully differentiated between BE and NBE formulations, consistent with the clinical BE results. Dissolution testing using biorelevant BCB and Apex-V predicted the clinical BE/NBE of ECP-ESOs. The floating lid method enabled the practical use of BCB, while Apex-V prevented coning. This simple, yet biorelevant, dissolution test could help to predict clinical BE in formulation development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sawai Pharmaceutical Co., Ltd., 5-2-30 Miyahara, Yodogawa-ku, Osaka 532-0003, Japan.
- Molecular Pharmaceutics Lab., College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga 525-8577, Japan.
Zitieren
APA
Fushimi, M., Nakamichi, K., Nakatani, M., & Sugano, K. (2026). Development of a Biorelevant Dissolution Test Using Bicarbonate Buffer and Apex Vessel to Predict Clinical Bioequivalence. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.c25-00583
Vancouver
Fushimi M, Nakamichi K, Nakatani M, Sugano K. Development of a Biorelevant Dissolution Test Using Bicarbonate Buffer and Apex Vessel to Predict Clinical Bioequivalence. Chemical and Pharmaceutical Bulletin. 2026. doi:10.1248/cpb.c25-00583
BibTeX
@article{Fushimi2026,
author = {Fushimi, Masahiro and Nakamichi, Katsuki and Nakatani, Masatoshi and Sugano, Kiyohiko},
title = {Development of a Biorelevant Dissolution Test Using Bicarbonate Buffer and Apex Vessel to Predict Clinical Bioequivalence},
journal = {Chemical and Pharmaceutical Bulletin},
year = {2026},
doi = {10.1248/cpb.c25-00583}
}
EUVIMED